Anhand von 24 retrospektiv analysierten Fällen mit hypophysärem Riesenwuchs aus 14 verschiedenen Kliniken innerhalb der letzten 3,5 Jahrzehnte werden die klinische Symptomatik, die endokrinologische und bildgebende Diagnostik und die gewählten Therapieansätze mit ihren Langzeitverläufen verglichen und diskutiert. Gegenwärtige Therapie der Wahl ist die selektive operative Resektion des Wachstumshormon-produzierenden Hypophysenadenomes, gegebenenfalls ergänzt durch eine medikamentöse Behandlung mit Somatostatin-Analoga und/oder Dopamin-Agonisten sowie durch eine Strahlentherapie. Für die größten Fortschritte im Verlauf der Studie, verbunden mit verbesserten Prognosen, ist in erster Linie die weiterentwickelte Operationstechnik verantwortlich, in geringerem Maße auch die Pharmako- und Radiotherapie.     «

Anhand von 24 retrospektiv analysierten Fällen mit hypophysärem Riesenwuchs aus 14 verschiedenen Kliniken innerhalb der letzten 3,5 Jahrzehnte werden die klinische Symptomatik, die endokrinologische und bildgebende Diagnostik und die gewählten Therapieansätze mit ihren Langzeitverläufen verglichen und diskutiert. Gegenwärtige Therapie der Wahl ist die selektive operative Resektion des Wachstumshormon-produzierenden Hypophysenadenomes, gegebenenfalls ergänzt durch eine medikamentöse Behandlung mi...     »

This retrospective multicenter analysis of 24 patients with pituitary gigantism over a period of 3.5 decades compares and discusses the clinical manifestations, the biochemical and radiologic diagnosis and the treatment with its long-term outcome and sequelae. Patient characteristics: 16 male, 8 female patients with an estimated duration of excessive growth before diagnosis of 1-11 (mean 3,9) years, age at diagnosis between 3 and 21 years, height of +2.4 to 9.4 SD. Macrocephaly was present in 8 of 13, obesity in 10 of 24, visual field defects in 4, neurologic signs and symptoms in 3, and orthopedic signs and symptoms in 8 patients, bone age identical to chronologic age or mildly advanced. Maximum basal GH levels ranged between 14 and 400 ng/ml (mean 88,4), non-suppressible by oral glucose in 21 of 21 patients, IGF-1 elevated in 13 of 14, IGFBP-3 elevated in 8 of 8, impaired glucose tolerance in 5 of 17, hyperprolactinemia in 8 of 18, and normal pituitary function (other than GH and PRL) in 17 of 20 cases. Treatment: Transsphenoidal (17) or transcranial (3) operation or both consecutively (4) revealed GH-secreting pituitary micro- (7) or macroadenomas (17) which were acidophilic (21), partly (2) or exclusively (1) chromophobic or chromophobic on reoperation (1). Long-term cure was achieved by surgery alone in 7 patients, 5 of whom had microadenomas. Among the 17 patients with unsatisfactory surgical results, dopamine agonists were almost ineffective in all 10 patients, somatostatin analogues were effective in 4, incompletely effective in 4 and ineffective in 1 of 9 patients, conventional radiotherapy was effective in 2 patients and insufficiently effective in 1, stereotactic radiosurgery was effective in 1 of 2 patients, and iridium implantation was ineffective in 1 patient. Side effects included panhypopituitarism after surgery (5) and conventional radiotherapy (3), diabetes insipidus (6), bilateral hemianopsia (1), transient CSF leakage (2), hygroma (1) and hyperphagia (2) after surgery, anaplastic carcinoma 5 years after iridium implantation (1), and mental impairment after consecutive surgery, drug treatment and stereotactic radiosurgery (1). Conclusions: There has been a trend towards better surgical results and less iatrogenic morbidity over the last generation. Most important prognostic factors, besides surgical skill, is the preoperative tumor size and extension. To further improve the long-term prognosis it would be necessary to shorten the delay of diagnosis, to obtain novel drugs which would have to effectively achieve tumor shrinkage and GH normalization, and to optimize current radiotherapy modalities.     «

This retrospective multicenter analysis of 24 patients with pituitary gigantism over a period of 3.5 decades compares and discusses the clinical manifestations, the biochemical and radiologic diagnosis and the treatment with its long-term outcome and sequelae. Patient characteristics: 16 male, 8 female patients with an estimated duration of excessive growth before diagnosis of 1-11 (mean 3,9) years, age at diagnosis between 3 and 21 years, height of +2.4 to 9.4 SD. Macrocephaly was present in 8...     »